Kratom and 7-OH dependence is showing up in addiction clinics at scale

Addiction clinics across the US are reporting a meaningful increase in patients presenting with dependence and withdrawal from kratom and its more potent derivative, 7-hydroxymitragynine (7-OH). These products, widely sold in gas stations and online as unregulated supplements, are now producing clinical withdrawal syndromes that require active management.

Why it matters

Kratom has been circulating in clinical conversations for years, but 7-hydroxymitragynine changes the risk profile substantially. 7-OH is a partial opioid agonist with receptor binding potency that outstrips morphine in preclinical models, and concentrated 7-OH products are now commercially available without a prescription. The withdrawal syndrome mirrors opioid withdrawal closely enough that standard COWS scoring applies, but standard urine drug screens do not detect it. That gap between clinical presentation and diagnostic confirmation is where patients get missed.

The practical implication for clinicians is straightforward: the substance use history needs to explicitly include kratom, 7-OH, and related products by name, not just as a catch-all question about supplements. Treatment protocols are still being worked out, but buprenorphine has shown utility in managing withdrawal in case reports and small series. What addiction clinics are seeing now is likely the leading edge of a larger wave, particularly as higher-potency 7-OH formulations become more accessible and more aggressively marketed to people trying to self-manage opioid cravings or chronic pain.

What to watch

Whether the FDA moves to schedule 7-OH specifically, given its significantly higher mu-opioid receptor potency compared to kratom's primary alkaloid mitragynine.